Xencor (NASDAQ:XNCR) Hits New 52-Week Low – Time to Sell?

Xencor, Inc. (NASDAQ:XNCR)’s share price reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $12.23 and last traded at $12.61, with a volume of 61223 shares traded. The stock had previously closed at $12.95.

Wall Street Analyst Weigh In

XNCR has been the subject of a number of recent analyst reports. Wells Fargo & Company lowered their price target on Xencor from $37.00 to $33.00 and set an “overweight” rating for the company in a research note on Friday, February 28th. StockNews.com lowered shares of Xencor from a “hold” rating to a “sell” rating in a report on Friday, March 14th. Finally, Piper Sandler raised shares of Xencor from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $20.00 to $30.00 in a report on Monday, December 2nd. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $34.38.

Xencor Stock Performance

The firm has a market cap of $779.31 million, a price-to-earnings ratio of -3.46 and a beta of 0.74. The stock has a 50-day moving average of $15.89 and a 200-day moving average of $20.21. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.19. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The company had revenue of $52.79 million for the quarter, compared to the consensus estimate of $17.14 million. As a group, analysts anticipate that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Institutional Trading of Xencor

Several institutional investors and hedge funds have recently bought and sold shares of XNCR. Point72 Asset Management L.P. lifted its stake in Xencor by 147.3% in the 3rd quarter. Point72 Asset Management L.P. now owns 3,120,229 shares of the biopharmaceutical company’s stock valued at $62,748,000 after purchasing an additional 1,858,440 shares during the last quarter. RTW Investments LP lifted its position in shares of Xencor by 317.9% during the 4th quarter. RTW Investments LP now owns 2,402,883 shares of the biopharmaceutical company’s stock valued at $55,218,000 after acquiring an additional 1,827,883 shares during the period. BVF Inc. IL grew its stake in Xencor by 169.3% during the fourth quarter. BVF Inc. IL now owns 2,288,760 shares of the biopharmaceutical company’s stock worth $52,596,000 after buying an additional 1,438,760 shares in the last quarter. Nuveen Asset Management LLC boosted its position in shares of Xencor by 452.4% during the 4th quarter. Nuveen Asset Management LLC now owns 837,082 shares of the biopharmaceutical company’s stock worth $19,236,000 after acquiring an additional 685,557 shares in the last quarter. Finally, Finepoint Capital LP acquired a new stake in shares of Xencor in the 4th quarter valued at $15,167,000.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.